#Gabriel Tarrasón Risa, Lead AI Scientist #Rejuvenate Biomed, will present at Science for Health on 12 Nov, Brussels. Gabriel will dive into the capabilities of CombinAge™ and the power of graph ML for discovering novel targets and drug combinations. #GraphML #AI #DrugDiscovery

This week Ann Beliën of @Rejuvenate Biomed attends the Society Of The World on sarcopenia, cachexia, and Wasting Disorders (SCWD2024), the Cachexia Regulatory & trials update workshop, to discuss the potential role of RJx-01 to tackle sarcopenia, cachexia, related conditions. #SCWD2024

Dr. Ann Beliën, Founder & CEO of Rejuvenate Biomed, will join the prestigious Global Healthspan Summit 2025 in Riyadh, Saudi Arabia: Insights on funding, innovation, regulation & sustainable growth in biotech, 5 Feb 2025, 08:30am – 09:45am #GlobalHealthspanSummit

Valuable to see that @Pharma's Almanac is creating awareness of the importance of AI in drug development: AI is undeniably transforming drug development and therapeutics innovation, from target identification and drug discovery acceleration pharmasalmanac.com/articles/is-ai…

#WorldObesityDay, @RejuvenateBiomed is tackling muscle strength loss in obesity treatment with innovative combination therapies to enable faster functional performance. #BiotechInnovation #ObesityAwareness #WOD2025 #WorldObesityDay #ObesityAwareness #HealthForAll #ChronicDisease

Jeroen Aerssens (Rejuvenate Biomed ) presents the clinical development of RJx-01, a novel combination drug targeting sarcopenia in older adults. #HealthyAging #Sarcopenia #ClinicalResearch #Geroscience

Rejuvenate Biomed will speak at the 3rd Health from Space International Congress on April 2-3, 2025, in Cannes, France. Founder & CEO, Ann Beliën, PhD, will speak: April 2: 11:50 – 12:50 | Space: From regenerative medicine to cosmetics 18:15 – 19:00 | Space for longevity

Rejuvenate Biomed will be attending the WCO-IOF-ESCEO Congress in Rome, April 10–13, by Jeroen Aerssens, PhD (Chief Development Officer), and Ann Beliën, PhD (Founder & CEO). Presentation: P1577 early clinical development plans for RJx-01 in sarcopenia: Sunday, April 13, 9am-10am.

Back from WCO (IOF-ESCEO) Rome with Ann Beliën & Jeroen Aerssens — great discussions on sarcopenia, osteoporosis & musculoskeletal health. Rejuvenate Biomed presented RJx-01 poster — a promising candidate for unmet needs in sarcopenia. #RJx01 #Sarcopenia #MuscleHealth

Rejuvenate Biomed at the GLP-1 Based Therapeutics Summit Boston (April 29–May 1), Dr Ann Beliën, RJx-01 lead Phase 2 asset for muscle quality protection in patients on GLP-1 therapies. Data on RJx-01’s multitarget approach to preserving muscle, regardless of the underlying cause.

Excited to share our story at Corda Campus Day GGDT! Our Lead Scientist, Jolien Van Houcke, PhD, will present Rejuvenate Biomed’s AI-driven approach to tackling age-related diseases to 3rd bachelor Biomedical students at U Hasselt.

🌟 Rejuvenate Biomed is excited to share new insights at #BioEquityEurope2025 in Bruges! 🗓️ Tue, May 13 at 11:15am CET 📍 Room 7+8 | Musculoskeletal track CEO Ann Belien, PhD, will present our latest innovations, joined by CFO Lizzy-Anne Neven. Let’s connect!

We are thrilled to announce that today, the first patient has been dosed in our Phase 2 clinical trial evaluating our lead investigational compound to treat muscle weakness and sarcopenia in patients with chronic obstructive pulmonary disease (COPD). lnkd.in/evhsNepM

Rejuvenate Biomed joins 1st Annual European Biopharma Obesity Innovation Forum Leipzig (#Sachs_EBOIF). Ann Belien, PhD, on the “Next Gen Therapeutics” panel – June 11 @ 10:25am CET; Company presentation @ 12:00pm CET: RJx-01 & muscle quality innovation lnkd.in/ejruNeMA

Explore Jo Shorthouse’s latest article on Europe’s shifting funding landscape. Dr. Ann Beliën, shares how Rejuvenate Biomed is navigating today’s investment climate with a long-term vision and purpose-driven science. linkedin.com/posts/jo-short…

Rejuvenate Biomed is proud to sponsor and speak at #ARDD2025 in Copenhagen! We’ll present RJx-01, our Phase 2 therapy for sarcopenia — powered by our AI-driven CombinAge™ platform. Join us to explore the future of healthy aging! #HealthyAging #MuscleHealth #Sarcopenia #ARDD2025

Excited to share that Jeroen Aerssens, PhD, CDO of Rejuvenate Biomed, will present at #ARDD2025 in Copenhagen. 🗓️ Wed, 27 Aug | 🕥 10:50–11:10 CET | 📍 Ceremonial Hall, Topic: Clinical update on RJx-01 — our Phase 2 oral therapy for sarcopenia. #HealthyAging #LongevityScience

Jeroen Aerssens, PhD, presented updates on RJx-01, our Phase 2 asset for sarcopenia and highlighted human MoA data showing RJx-01’s capability to improve mitochondrial energy production and to reduce inflammation and collagen deposition. Proud sponsor. #AgingResearch #ARDD

Join us at the Obesity Drug Development Summit (Oct 1–2), Barcelona, where our CEO Ann Beliën, PhD, will present RJx-01, our Phase 2 therapy targeting age-related muscle decline. Day 2: 🧬 10:00 – Company Presentation 💬 11:45 – Panel Discussion 🤝 12:30 – Roundtable

Proud to support the next generation of biotech leaders! 📍 On Oct 2, Jolien Van Houcke, PhD, will present at #OPINNO @UHasselt, joined by Evi Mercken, PhD, for roundtable talks. Let’s inspire future innovators! 💡🔬 #STEM #LifeSciences #RejuvenateBiomed